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Abstract
Prostate cancer is the most common non-skin cancer and the second leading cause of cancer related mortality for men in
the United States. There is strong empirical and epidemiological evidence supporting a stronger role of genetics in early-
onset prostate cancer. We performed a genome-wide association scan for early-onset prostate cancer. Novel aspects of this
study include the focus on early-onset disease (defined as men with prostate cancer diagnosed before age 56 years) and use
of publically available control genotype data from previous genome-wide association studies. We found genome-wide
significant (p,561028) evidence for variants at 8q24 and 11p15 and strong supportive evidence for a number of previously
reported loci. We found little evidence for individual or systematic inflated association findings resulting from using public
controls, demonstrating the utility of using public control data in large-scale genetic association studies of common
variants. Taken together, these results demonstrate the importance of established common genetic variants for early-onset
prostate cancer and the power of including early-onset prostate cancer cases in genetic association studies.
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Introduction
Prostate cancer (PCa) is a leading cause of cancer mortality in
men. In 2013, it is estimated that 238,590 men will be diagnosed
with and 29,720 men will die from the disease [1]. Approximately
1 in 6 men will be diagnosed with PCa during their lives based on
the current incidence rates [1,2]. The major recognized risk
factors for PCa are increasing age, African ancestry and positive
family history.
Genome-wide association (GWA) studies and follow-up studies
have identified and replicated ,65 single-nucleotide polymor-
phisms (SNPs) that are associated with PCa in men of European
descent [3–17]. Most of these studies have included primarily
older PCa cases, reflecting the demographics of the disease as well
as, in some cases, study design constraints. For most complex
disorders, including common cancers, early age at diagnosis is a
marker of heritable forms of the disease. Among hereditary PCa
families, disease is diagnosed 6–7 years younger than sporadic
disease and the risk for PCa increases with decreasing age of
affected family members [18]. Further, studies have suggested that
men diagnosed with PCa earlier in life are more likely to die from
their disease compared to men, with similar clinical features of
disease, diagnosed at an older age [19,20]. To assess the
importance of common genetic variants to early-onset PCa, we
performed a GWA study for early-onset PCa, defined here as PCa
diagnosed prior to age 56 years, in 931 men of European descent
who were diagnosed with PCa at an average age of 49.7 years and
4120 European descent controls. This study represents the largest




The University of Michigan IRBMED has reviewed and
approved the scheduled continuing review (SCR) submitted for
the University of Michigan Prostate Cancer Genetics Project. The
IRB determined that the proposed research continues to conform
with applicable guidelines, State and federal regulations, and the
University of Michigan’s Federal-wide Assurance (FWA) with the
Department of Health and Human Services (HHS). All University
of Michigan subjects included in this study provided written
informed consent to participate in the study; the protocol and
consent documents were approved by the Institutional Review
Board at the University of Michigan Medical School.
Genotype data from follow-up samples for this study were
obtained from Johns Hopkins University (JHU). This human
subjects research proposal was reviewed and approved by the
Johns Hopkins Medicine Institutional Review Board (JHM IRB).
JHU PCa case DNA were obtained from de-identified patholog-
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ical specimens and determined, by JHM IRB, to be exempt from
the requirement of written or oral consent. Follow-up control
DNA samples were obtained from PCa screened men negative for
the disease. All JHU controls provided written informed consent;
the protocol and consent documents were approved by JHM IRB.
Analyses for this study were conducted at the University of North
Carolina at Chapel Hill using de-identified data. The University of
North Carolina Institutional Review Board approved the
proposed study. Data material transfer agreements were signed
between officials at the University of North Carolina, University of
Michigan and Johns Hopkins University.
Study Samples
The final study case sample included 931 successfully genotyped
unrelated early-onset PCa cases (diagnosed prior to age 56 years)
of European descent from the University of Michigan Prostate
Cancer Genetics Project (UM-PCGP). Descriptive information
about the cases is presented in Table 1. The average (standard
deviation) and median age (range) of prostate cancer diagnosis in
these 931 cases was 49.7 (4.1) years and 50 (27–55) years,
respectively. Of note, this sample of men is enriched for positive
family history (576/931 or 61.9% with reported first or second
degree relatives with PCa), partially a consequence of some
samples (n = 127) being ascertained from families included in the
UM-PCGP linkage study on hereditary PCa. Descriptions of the
UM-PCGP hereditary PCa families can be found elsewhere
[21,22]. A total of 351 cases came from families that had DNA
collected on multiple cases; 817/931 cases were either family
probands or ascertained directly due to early age at diagnosis. In
families that had more than one PCa case diagnosed prior to age
56 years, only the youngest available case was included in the
current study. Clinical features of UM-PCGP early-onset PCa
cases are presented in Table 1.
Unrelated controls with GWA study SNP data were selected
from publically available resources through dbGap (www.ncbi.
nlm.nih.gov/gap) and Illumina (www.illumina.com). Controls
were selected to have European reported ancestry and genotype
data generated from a GWA study commercial platform similar to
the platform used in UM-PCGP cases. To maintain independent
results from prior published PCa GWA studies, public controls
that were used in these prior PCa studies were excluded from
consideration. Controls, which included women, were not, to our
knowledge, screened for PCa. Controls came from the Cancer
Genetics Markers of Susceptibility (CGEMS) (n = 1135) GWA
study for breast cancer [23] and Illumina’s iControlDB database
(n = 2985) (www.Illumina.com). Only CGEMS breast cancer
controls were included. Limited descriptive information, including
age, gender and ancestry, on selected iControlDB subjects can be
obtained from the Illumina website. The rationale for including
female controls is provided in the Discussion. Separate analyses
including only male iControlDB subjects were also performed.
A subset of novel SNPs (p,5.061025 and not previously
reported to be associated with PCa) were analyzed in an additional
sample of 2571 unrelated PCa cases (1053 diagnosed prior to age
56 years) and 921 screened controls of European-descent from
JHU (see Ewing et al. [24] for description of subjects).
Genotyping
938 European-American UM-PCGP early-onset PCa cases
were initially genotyped at Wake Forest University using
Illumina’s HumanHap 660W-Quad v1.1 BeadChip. CGEMS
Breast cancer controls were genotyped previously using Illumina’s
HumanHap550v1 [23]. The iControlsDB subjects were geno-
typed previously using Illumina’s HumanHap550v1 (n = 1478) or
HumanHap550v3 (n = 1507) commercial genotyping platforms.
Follow-up genotyping on JHU subjects was performed at Wake
Forest University using the Sequenom system. All the procedures
followed the manufacturer’s iPLEX Application Guide (Seque-
nom, Inc. SanDiego, CA) and all the assay reagents were
purchased from Sequenom. To ensure the quality of the
genotyping, around 2% of the sample duplicates and 2% of the
negative controls, in which water was substituted for DNAs, were
applied.
Statistical Analyses
Genotyping quality control (QC) methodology was uniformly
applied to all samples. To reduce the possible impact of bias due to
‘‘batch’’ genotyping effects, SNPs missing genotype calls in .2%
of subjects in any of the four sample sets (UM-PCGP cases,
CGEMS breast cancer controls, Illumina iControls V1 or
iControls V3) were excluded. Subjects missing .5% of SNP
genotyping calls were also excluded. For UM-PCGP cases,
genotyping calls between Illumina’s HumanHap 660W-Quad
v1.1 BeadChip results and 14 SNPs previously genotyped using
TaqMan [25] were compared to verify sample identity and to
assess the overall concordance of genotype calls between the two
platforms. In addition, 21 duplicate samples were included to
assess concordance of genotype calls with the Illumina’s Human-
Hap 660W-Quad v1.1 BeadChip results. Laboratory personnel
were blinded to the identity of the duplicates. European ancestry
for all subjects, including controls, was verified using the software
ADMIXTURE [26]; subjects with apparent misidentified ancestry
or mixed ancestry were removed from consideration.
Genotype imputation was performed to expand the coverage of
variants in our GWA study to SNPs that were not included on
Illumina’s HumanHap 660W-Quad v1.1 BeadChip or that were
included on the BeadChip but were lost during QC, using the
software package MaCH [27,28]. Genotype imputation was
performed separately including SNPs from HapMap Phase II
(CEU reference samples) and HapMap Phase III (CEU+TSI
reference samples). Imputed genotype data were analyzed as
dosage values (expected number of copies of the minor alleles) in





Age at Diagnosis (years) 49.7 (4.1) 50 (27–55)
Prediagnostic PSA (mg/dL)2 20.6 (199.5) 5.2 (0.4–5428)









1Includes 20 metastatic cases and 32 cases with lymph node involvement.
2Prediagnostic PSA available on 870 cases.
3Gleason scores available on 920 cases. Note: Prostatectomy Gleason used
when available (n = 787), otherwise biopsy Gleason scores used (n = 133).
4T Stage available on 804 cases.
doi:10.1371/journal.pone.0093436.t001
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logistic regression models implemented in Mach2dat [28]. The
logistic regression models included covariate adjustment for the
first 10 principal components for ancestry and/or batch effects.
Principal component analysis was performed using the software
Eigenstrat [29] on the combined sample of cases and controls
using a linkage-disequilibrium (LD) pruned set of SNPs. All
genotype data for SNPs that were excluded based on quality
control analyses due to genotype-missing rates in one or more of
the four sample sets were zeroed out in all four target sample sets
prior to imputation to reduce the possibility of batch genotype
effects impacting the imputation-based SNP association results.
Preference was given to Phase III imputation results when a SNP
was successfully imputed using both Phase II and Phase III
HapMap samples. Genome-wide significance was defined as
p,5.061028. Chromosome X variants were not imputed.
Single variant association analyses for directly genotyped SNP
data were also performed using the software PLINK [30]. Logistic
regression models were systematically analyzed with covariate
adjustment for the first 10 principal components derived from
Eigenstrat. Only SNPs that were genotyped .98% rate in all four
sets of samples were included in the genotyped-SNP analyses.
Chromosome X analyses were performed on directly genotyped
SNPs and limited to include only the 1126 male iControlDB
subjects.
A subset of SNPs reaching p,561025 in the GWA study were
followed up in an independent sample of 2571 PCa cases and 921
screened controls from JHU. SNPs were analyzed individually
using chi-square tests. Subset analyses were performed restricting
cases to those (n = 1053) diagnosed with PCa prior to age 56 years.
Results
592,652 SNPs were genotyped on 938 unrelated European-
American UM-PCGP cases with early-onset PCa. QC analyses
were conducted to assess overall accuracy and completeness of
genotype data. Five UM-PCGP subjects were removed for low
genotype rate (,95% of SNPs with genotype data). Two
additional UM-PCGP subjects had large estimated proportions
of non-European ancestry and were removed. After sample
removal, a total of 931 unrelated UM-PCGP PCa cases passed
QC and were included in the study. Genotype concordance rates
between HumanHap 660W-Quad v1.1 BeadChip and Taqman
genotype calls was .99% and internal concordance of Human-
Hap 660W-Quad v1.1 BeadChip calls in 21 duplicate pairs was
.99.99%.
A total of 458,162 autosomal SNPs with a successful genotyping
rate .98% in each sample (UM-PCGP, CGEMS breast cancer
controls, iControls V1, iControls V3) were included in the final
target set for genotype imputation. Genotype imputation allowed a
total of 2,639,562 autosomal SNPs, with MaCH imputation
quality score R2 .0.3, to be analyzed for association with PCa.
Results across the genome are graphically illustrated in Figure 1
and the top findings (p,1.061025) are presented in Table 2. The
top result was for an uncommon (minor allele frequency estimated
to be 1.5% in combined case-control sample) chromosome 13
SNP rs11839053 (p = 8.7610210) based on HapMap Phase II
imputation data. For reasons described in the Discussion, we
believe the result for this SNP should be considered with caution.
Two established 8q24 SNPs (rs10505477, p = 9.461029;
rs6983267, p = 1.261028) and two established 11p15 SNPs
(rs7126629, p = 2.361028; rs7114836, p = 3.761028) also reached
genome-wide significance. The top novel results were for
Chromosome 18 SNP rs11664910 (p = 2.361026) and Chromo-
some 17q21-22 SNP rs8064701 (p = 4.861026).
Results for analyses of directly genotyped SNPs were consistent
with results from the imputed genotype data for SNPs included in
both datasets (data not shown). Of note, rs6983267 also reached
genome-wide significance in the genotyped-SNP analyses
(p = 1.361028). Little evidence for a systematic inflated type I
error was observed when taking into account the distribution of all
results (genomic inflation factor 1.026) [31]. A total of 11,397
directly genotyped SNPs on chromosome X were also analyzed;
the top finding was located at rs5906300 (p = 8.161025) and there
was no evidence for any systematic inflation of type I error across
the X chromosome (Genomic inflation factor = 1.00).
Thirty-nine SNPs previously reported to be associated with PCa
in men of European descent, summarized in Goh et al. [32], were
evaluated for confirmatory evidence in our study of men with early
onset disease (Table 3). Twenty-three out of 39 SNPs were at least
nominally significant (p,0.05) in the current study; all 23 had
directions of effect consistent with the previous reports. Twelve of
the 16 SNPs that did not reach nominal significance also had
direction of effect consistent with the previous reports. Estimated
imputation quality for the vast majority of these SNPs was
excellent.
Results from association analyses only including the 1126 male
iControlDB subjects were similar to those obtained using the
larger sex-combined control sample. Genome-wide significant
findings were obtained for the two aforementioned chromosome
8q24 SNPs (rs10505477, p = 1.761029; rs6983267, p = 1.861029)
and known chromosome 17 TCF2-intronic SNP rs4430796
(p = 4.161028). Chromosome 11p15 SNPs rs7126629
(p = 1.661026) and rs7114836 (p = 9.961026) and Chromosome
13 SNP rs11839053 (p = 1.261024) did not reach genome-wide
significance when using the smaller control sample.
Thirteen independent SNPs that demonstrated strong nominal
association with PCa (defined here as p,561025), when using the
complete control sample, and that have not been previously
implicated to be associated with PCa were genotyped and tested
for association with PCa in an independent sample of 2571
unrelated European-descent PCa cases and 921 screened controls
from JHU. When results were similar between the top imputed
SNP and a directly genotyped SNP in the same region, the SNP
directly genotyped was selected for follow-up. Only one SNP,
rs11664910, reached nominal significance (p,0.05); however, the
direction of effect for this SNP was not consistent with the initial
GWA study result (Table 4). Results were similar when restricting
the follow-up case sample to cases diagnosed prior to age 56 years
(data not shown).
Discussion
From 2005–2009, the average age at PCa diagnosis in the
United States was 67 years and only ,10% of cases were
diagnosed prior to age 55 years [1]. Given the small proportion of
PCa cases diagnosed in this age range, most genetic studies for
PCa are concentrated on men diagnosed with the disease later in
life despite the evidence that early age at diagnosis is an indicator
of increased genetic susceptibility. For example, a Swedish study
has shown that family history is particularly important in men who
have one or more first-degree relatives that were diagnosed with
PCa at a relatively young age [19]. The relative risk for developing
PCa for a man whose father had been diagnosed with PCa at age
60 or older was estimated to be 1.5. The relative risk for
developing PCa increased to 2.5 if the father was diagnosed prior
to 60 years of age. Similarly, if one brother was diagnosed with
PCa at age 60 or older then the relative risk for a man developing
PCa was estimated to be 2 whereas the relative risk was estimated
Early-Onset Prostate Cancer Genome-Wide Scan
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to be 3 if that brother was diagnosed with PCa prior to age 60
[19]. In a meta-analysis, the risk of PCa was shown to increase
with decreasing age at PCa diagnosis of a first-degree relative [20].
We describe a GWA study for early-onset PCa based entirely of
cases diagnosed with the disease prior to age 56 years. A single
novel locus, chromosome 13 SNP rs11839053 (p = 8.7610210),
reached genome-wide significance (p,561028), though we urge
caution in interpreting this result (see below). A total of four
variants in known regions of PCa association reached genome-
wide significance: two 8q24 variants, rs6983267 (p = 9.561029)
and rs10505477 (p = 9.461029), and two 11p15 variants,
rs7126629, (p = 2.361028) and rs7114836, (p = 3.761028). In
addition to these loci, there was strong supportive evidence at a
number of previously established PCa loci (Table 3). Of note, for
the established loci the observed odds ratios were comparable to
the odds ratios in the initial discovery studies despite the likely
upwards biased odds ratio estimates in the original reports, due to
the ‘‘winners curse’’ phenomenon in SNP association discovery
[33], and the use of female and unscreened male controls in the
current study.
In this report, we observed one novel significant association for
chromosome 13 SNP rs11839053 based on HapMap Phase II
imputation data (p = 8.7610210). We noted a strong discrepancy
between results from HapMap Phase II (p = 1.061029) and Phase
III (p = 0.98) imputation results for neighboring SNP rs11843540,
which is in strong LD with rs11839053 (R2 = 1.0 in HapMap
Phase II CEU samples). Rs11839053 was not genotyped in
HapMap Phase III samples. The strong discrepancy between
results for rs11843540 based on Phase II and Phase III imputation
data was the only noted major difference between these two data
sets across all SNPs that were imputed using both reference
samples; results were also highly concordant between genotyped
and imputed SNPs (Spearman’s correlations: 0.98, 0.98, 0.96,
between results for Phase II vs. genotype, Phase III vs. genotype,
and Phase III vs. Phase II, respectively). Interestingly, the
significant result at rs11839053 was also observed when restricting
analyses to the CGEMS breast cancer controls and when
analyzing imputed genotype data generated using 1000 Genomes
Project data (3rd release) as the reference panel (data not shown).
We note that imputation qualities for rs11839053 and rs11843540
were relatively poor (r2,0.6 in all reference panels for each SNP),
we observed little evidence for association (all p.0.001) for any
directly genotyped SNPs in the 500 kb region immediately
surrounding the two SNPs, and we did not observe any evidence
for association at rs11839053 in our follow-up study of 2571 cases
and 921 screened controls from JHU (Table 3). While our study
using public controls appeared to have good overall control of type
I error, any individual result should be considered suspect. It is
unclear whether the result at rs11839053 in our GWA study is an
artifact of using public control genotype data (i.e. ‘‘batch’’ effects
for one or more genotyped SNPs in the region impacting
imputation) or a true signal. Future studies will be necessary to
confirm the association result before the locus should be
considered a legitimate PCa locus.
We identified 12 additional novel regions that contained
variants that had suggestive evidence for association (defined here
as p,561025). A representative SNP was chosen in each region
and followed up in the JHU samples; no significant evidence
supporting any of the results in the initial study were observed
(Table 3). Arguably the most interesting result among these twelve
loci was for chromosome 17q21-22 imputed SNP rs8064701 and
nearby directly genotyped SNP rs7225566. Recently we discov-
ered an uncommon missense variant, G84E/rs138213197, in
HOXB13 that is associated with PCa [24]. The G84E variant is
,1.2 Mb proximal to rs8064701 and rs7225566. Among the 931
cases in the current study (which were also included in the initial
HOXB13 report), 23 (,2.5%) carried the variant allele at
HOXB13. We performed long-range haplotyping using FastPhase2
[34] and identified a single long-range haplotype that contained all
23 G84E variant alleles (a single case without the variant allele also
was predicted to have the same long-range haplotype). The
frequency of the minor (risk) allele for rs7225566 in the GWA
study was 15% in cases and 11% in controls. Fifteen of the 23
cases carrying the HOXB13 G84E risk allele also carried the
Figure 1. Manhattan Plot of Results for Imputed HapMap Phase II and Phase III SNPs.
doi:10.1371/journal.pone.0093436.g001
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minor/risk allele for rs7225566, including one homozygote. These
results suggest the observed nominally significant associations at
rs8064701 and rs7225566 are partially due to linkage disequilib-
rium with HOXB13 G84E. While there was a slight increase in
frequency of the rs7225566 risk allele in the JHU data (11% in
cases versus 10% in controls), the result did not reach statistical
significance. Finally, we note that rs7225566 is ,362 kb distal to
rs7210100, an uncommon variant which was previously identified
to be associated with PCa in a GWA study of African Americans
[35]. Rs7210100 was not directly genotyped or successfully
imputed, due to the absence of Caucasian carriers in the HapMap
reference panels, in our GWA study samples. The absence/rarity
of the risk allele for rs7210100 in populations of European descent
strongly suggests our finding at rs7225566 is independent of this
previous reported variant. Of note, as previously reported
(Supplemental Material of Ewing et al. [24]), among 24 African
Table 3. Results at established PCa loci in men of European descent based on loci presented in Goh et al. [32]. Results presented
for imputed SNPs.
Locus SNP (Rare/Common1)
Per allele OR Discovery
Study
Per allele OR Current
Study P-value Imputation Quality (R2)
2p11 rs10187424 (G/A) 0.92 0.94 0.27 1.00
2p15 rs721048 (A/G) 1.15 1.17 0.021 1.00
2p21 rs1465618 (A/G) 1.08 1.04 0.57 0.94
2q31 rs12621278 (G/A) 0.75 0.58 5.261025 1.00
2q37 rs2292884 (G/A) 1.14 1.08 0.18 1.00
3p12 rs2660753 (T/C) 1.18 1.09 0.29 0.99
3q21 rs10934853 (A/C) 1.12 1.09 0.15 1.00
3q23 rs6763931 (T/C) 1.04 1.10 0.074 1.00
3q26 rs10936632 (C/A) 0.90 0.84 0.0035 0.75
4q22 rs17021918 (T/C) 0.90 0.97 0.59 0.99
4q22 rs12500426 (A/C) 1.08 1.14 0.012 0.99
4q24 rs7679673 (A/C) 0.91 0.88 0.017 0.98
5p12 rs2121875 (G/T) 1.05 0.99 0.84 1.00
5p15 rs2242652 (A/G) 0.87 0.88 0.23 0.49
6p21 rs130067 (G/T) 1.05 0.98 0.80 1.00
6q25 rs9364554 (T/C) 1.17 1.24 1.961024 1.00
7p15 rs10486567 (A/G) 0.74 0.83 0.0038 1.00
7q21 rs6465657 (C/T) 1.12 1.17 0.0025 1.00
8p21 rs2928679 (T/C) 1.05 0.96 0.51 1.00
8p21 rs1512268 (A/G) 1.18 1.23 1.261024 1.00
8q24 rs1447295 (A/C) 1.62 1.38 7.861025 1.00
8q24 rs6983267 (G/T) 1.26 1.36 9.561029 1.00
8q24 rs16901979 (A/C) 1.79 1.39 0.010 1.00
8q24 rs10086908 (T/C) 0.87 0.88 0.027 1.00
8q24 rs12543663 (C/A) 1.08 1.25 9.161025 1.00
8q24 rs620861 (A/G) 0.90 0.80 8.861025 0.97
9q33 rs1571801 (T/G) 1.27 1.06 0.29 0.99
10q11 rs10993994 (T/C) 1.25 1.32 1.961027 0.99
10q26 rs4962416 (C/T) 1.20 1.20 0.0014 1.00
11p15 rs7127900 (A/G) 1.22 1.40 1.061027 1.00
11q13 rs7931342 (T/G) 0.84 0.77 1.261026 1.00
12q13 rs10875943 (C/T) 1.07 1.05 0.37 1.00
12q13 rs902774 (A/G) 1.17 0.99 0.91 1.00
17q12 rs4430796 (A/G) 1.22 1.33 2.561026 0.75
17q12 rs11649743 (A/G) 1.28 1.10 0.17 1.00
17q24 rs1859962 (G/T) 1.20 1.21 2.661024 1.00
19q13 rs2735839 (A/G) 0.83 0.72 3.761025 1.00
22q13 rs5759167 (T/G) 0.86 0.84 0.0014 1.00
Xq12 rs5919432 (G/A) 0.94 0.93 0.56 Genotyped
1Rare allele is the coded effect/risk allele.
doi:10.1371/journal.pone.0093436.t003
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American rs7210100 risk-allele carriers, none carried the HOXB13
G84E risk allele.
Our initial discovery study included only publically available
control genotype data in contrast to using a gold-standard age-
matched screened control sample. The UM-PCGP, being a
family-based and case-only study, does not have access to an ideal
large control sample from the same population as the cases.
Disease misclassification, which would likely occur at higher rates
when using public control data, can cause a reduction in statistical
power to detect truly associated genetic loci. Most publicly
available control genotype data come from studies with very
limited information on PCa status. While there does exist
publically available genetic data on PCa screened controls from
previous PCa GWA studies, we elected to avoid using controls
from these studies in order to obtain independent results. We, and
others [36–39], have shown that genetic association studies
including larger numbers of unscreened controls generally have
greater power for discovery than studies using a smaller number of
screened controls provided the rate of disease misclassification is
not high. For our primary analyses, we chose to include both male
and female public controls over a control sample limited to
unscreened males. The prevalence of diagnosed PCa in European-
American men under 56 years of age is less than 1%, thus the rate
of disease misclassification for both our male and female public
controls should not be that much larger than it would have been
for age-matched screened controls from this age group.
The current study includes a large number of men with positive
family history of disease (576/931 had a first or second degree
relative with PCa). Some of this enrichment was directly due to
ascertainment criteria, but most is likely attributed to increased
rates of disease, due to both genetic susceptibility and enhanced
screening, in families with early-onset disease. This study adds to
the growing evidence that GWA study common variants play an
important role in familial and early-onset PCa [17,25,40,41]. As
new high-penetrant mutations are detected through next-genera-
tion sequencing, assessing the relative role of common risk variants
and rare mutations to familial disease clustering will become an
exciting area of research. For example, Karlsson et al. [42]
recently showed that carrying a HOXB13 G84E mutation [24],
which occurs at a frequency of ,1.3% in Sweden, is most strongly
associated with hereditary (OR = 6.6) and early-onset (OR = 8.6)
PCa and that the risk for G84E mutation carriers of developing
disease is increased significantly for those carrying a higher burden
of established common GWA study variants.
In conclusion, we describe results from the first stage of a two-
stage GWA study for early-onset PCa. Our two-stage study design
follows the strategy described by Ho and Lange [39], which
increases the power of traditional case-control GWA studies by
incorporating public control genotype data in the stage 1 discovery
phase. As is the case for any study using public control data, care
must be taken in interpreting any individual result due to factors
such as batch genotyping effects and differential selective pressures
across populations, which are difficult to completely control for
experimentally or analytically. Our results provide proof of
principal that such a study design is reasonable, given the strong
evidence at a number of previously established PCa loci and the
lack of evidence, with the possible exception of the chromosome
13 rs11839053 finding, for spurious results. In total, our results
provide compelling evidence supporting the importance of
common genetic variants to early-onset PCa.
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Table 4. Results for 13 SNPs with p,561025 in the GWA study in a follow-up study of 2571 PCa cases and 921 screened controls
from JHU.





Case/Control OR1 p-value R2
Freq Allele 1
Case/Control OR1 p-value
1 117717430 rs1146298 G/A 0.20/0.25 0.76 7.961026 1.00 0.24/0.25 0.99 0.93
1 152208138 rs11264743 T/C 0.35/0.30 1.26 4.561025 1.00 0.31/0.31 1.02 0.78
2 23628257 rs4665609 A/C 0.50/0.44 1.28 4.261026 1.00 0.45/0.46 0.93 0.19
4 60114549 rs10517468 G/T 0.22/0.27 0.77 1.161025 1.00 0.25/0.26 0.94 0.30
4 185567394 rs3775554 G/C 0.16/0.11 1.46 1.961025 0.80 0.12/0.12 0.96 0.61
6 133071135 rs12527885 C/T 0.04/0.07 0.56 1.561025 0.96 0.06/0.05 1.11 0.38
7 42574162 rs1880408 G/A 0.09/0.05 1.63 7.161026 0.98 0.06/0.07 0.85 0.15
8 8538732 rs7013418 G/T 0.29/0.23 1.35 3.761026 0.96 0.25/0.24 1.06 0.35
9 123990298 rs16911551 T/C 0.10/0.05 1.97 6.261026 0.46 0.04/0.03 1.22 0.19
13 105861043 rs11839053 C/T 0.05/0.01 4.02 8.7610210 0.65 0.04/0.05 0.87 0.29
14 82240475 rs2150333 T/A 0.04/0.08 0.50 2.961026 0.62 0.08/0.08 0.99 0.88
17 45153724 rs7225566 T/C 0.15/0.11 1.42 5.861026 1.00 0.12/0.11 1.14 0.13
18 57179043 rs11664910 G/A 0.45/0.38 1.34 2.361026 0.78 0.36/0.40 0.87 0.01
1Odds Ratio: Effect/risk allele is allele 1 (minor allele).
doi:10.1371/journal.pone.0093436.t004
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